These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28646924)

  • 1. Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial.
    Coldiron ME; Alcoba G; Ciglenecki I; Hitchings M; Djibo A; Page AL; Langendorf C; Grais RF
    Trials; 2017 Jun; 18(1):294. PubMed ID: 28646924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial.
    Coldiron ME; Assao B; Page AL; Hitchings MDT; Alcoba G; Ciglenecki I; Langendorf C; Mambula C; Adehossi E; Sidikou F; Tassiou EI; De Lastours V; Grais RF
    PLoS Med; 2018 Jun; 15(6):e1002593. PubMed ID: 29944651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of a meningococcal meningitis outbreak in Niger - potential effectiveness of reactive prophylaxis.
    Hitchings MDT; Coldiron ME; Grais RF; Lipsitch M
    PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007077. PubMed ID: 30856166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatiotemporal Analysis of Serogroup C Meningococcal Meningitis Spread in Niger and Nigeria and Implications for Epidemic Response.
    Cooper LV; Ronveaux O; Fernandez K; Lingani C; Goumbi K; Ihekweazu C; Preziosi MP; Durupt A; Trotter CL
    J Infect Dis; 2019 Oct; 220(220 Suppl 4):S244-S252. PubMed ID: 31671446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: an analysis of national surveillance data.
    Sidikou F; Zaneidou M; Alkassoum I; Schwartz S; Issaka B; Obama R; Lingani C; Tate A; Ake F; Sakande S; Ousmane S; Zanguina J; Seidou I; Nzeyimana I; Mounkoro D; Abodji O; Wang X; Taha MK; Moulia-Pelat JP; Pana A; Kadade G; Ronveaux O; Novak R; Oukem-Boyer OOM; Meyer S;
    Lancet Infect Dis; 2016 Nov; 16(11):1288-1294. PubMed ID: 27567107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response thresholds for epidemic meningitis in sub-Saharan Africa following the introduction of MenAfriVac®.
    Trotter CL; Cibrelus L; Fernandez K; Lingani C; Ronveaux O; Stuart JM
    Vaccine; 2015 Nov; 33(46):6212-7. PubMed ID: 26463444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid response to meningococcal disease cluster in Foya district, Lofa County, Liberia January to February 2018.
    Rude JM; Kortimai L; Mosoka F; April B; Nuha M; Katawera V; Nagbe T; Tamba A; Desmound W; Mulbah R; Pierre F; Onuche EM; Chukwudi JO; Talisuna A; Yahaya AA; Rajatonirina S; Nyenswah T; Dahn B; Gasasira A; Fall IS
    Pan Afr Med J; 2019; 33(Suppl 2):6. PubMed ID: 31404290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
    Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
    Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time delays in the response to the Neisseria meningitidis serogroup C outbreak in Nigeria - 2017.
    Hassan A; Mustapha GU; Lawal BB; Na'uzo AM; Ismail R; Womi-Eteng Oboma E; Oyebanji O; Agenyi J; Thomas C; Balogun MS; Dalhat MM; Nguku P; Ihekweazu C
    PLoS One; 2018; 13(6):e0199257. PubMed ID: 29920549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].
    Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV
    Sante; 1997; 7(6):384-90. PubMed ID: 9503496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa.
    Woods CW; Armstrong G; Sackey SO; Tetteh C; Bugri S; Perkins BA; Rosenstein NE
    Lancet; 2000 Jan; 355(9197):30-3. PubMed ID: 10615888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.
    Mohammed I; Iliyasu G; Habib AG
    Pathog Glob Health; 2017 Feb; 111(1):1-6. PubMed ID: 28081671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case-Fatality Rates and Sequelae Resulting from Neisseria meningitidis Serogroup C Epidemic, Niger, 2015.
    Coldiron ME; Salou H; Sidikou F; Goumbi K; Djibo A; Lechevalier P; Compaoré I; Grais RF
    Emerg Infect Dis; 2016 Oct; 22(10):1827-9. PubMed ID: 27649257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiological and epidemiological investigation of the Neisseria meningitidis serogroup A epidemic in Niger in 2009: last wave before the introduction of the serogroup A meningococcal conjugate vaccine?
    Collard JM; Maman Z; Abani A; Mainasara HB; Djibo S; Yacouba H; Maitournam R; Sidikou F; Nicolas P; Rocourt J; Jusot JF
    Epidemiol Infect; 2011 Nov; 139(11):1656-60. PubMed ID: 21251346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of meningococcal meningitis].
    Kastenbauer S; Grabein B; Pfister HW
    Nervenarzt; 2000 Feb; 71(2):134-7. PubMed ID: 10703016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidemiological and control aspects of meningococcal meningitis epidemics in Africa].
    Spiegel A; Moren A; Varaine F; Baudon D; Rey M
    Sante; 1994; 4(3):231-6. PubMed ID: 7921694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-Genome Characterization of Epidemic Neisseria meningitidis Serogroup C and Resurgence of Serogroup W, Niger, 2015.
    Kretz CB; Retchless AC; Sidikou F; Issaka B; Ousmane S; Schwartz S; Tate AH; Pana A; Njanpop-Lafourcade BM; Nzeyimana I; Nse RO; Deghmane AE; Hong E; Brynildsrud OB; Novak RT; Meyer SA; Oukem-Boyer OOM; Ronveaux O; Caugant DA; Taha MK; Wang X;
    Emerg Infect Dis; 2016 Oct; 22(10):1762-1768. PubMed ID: 27649262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
    Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
    Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of response strategies against epidemics due to Neisseria meningitidis C in Niger.
    Maïnassara HB; Oumarou GI; Issaka B; Sidiki A; Idi I; Pelat JM; Fontanet A; Mueller JE
    Trop Med Int Health; 2017 Feb; 22(2):196-204. PubMed ID: 27860062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.